技術摘要 / Our Technology: |
The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX with replacement at positions 86, 277, and 338 exhibits better clotting activity than recombinant wild type factor IX.
|
專利簡述 / Intellectual Properties: |
|
|
聯繫方式 / Contact: |
臺大產學合作總中心 / Center of Industry-Academia Collaboration, NTU |
|
Email:ordiac@ntu.edu.tw |
電話/Tel:02-3366-9945 |
|
|
|
|